For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors are ...
For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...
Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of ...
At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific ...
Covalent inhibitors represent a class of small molecules that form irreversible or quasi‐irreversible bonds with their protein targets, offering enhanced potency, prolonged duration of action and the ...
In a study published in Angewandte Chemie International Edition, a research team integrated activity-based protein profiling (ABPP) data with the covalent DNA-encoded chemical library (CoDEL) ...
Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors– First patient dosed in Phase 1b/2a ALS study with NB-4746, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results